NCT Number,Study Title,Study URL,Acronym,Study Status,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Age,Phases,Study Type,Study Design,Other IDs,Study Documents
NCT01901549,Renal Denervation in Patients After Acute Coronary Syndrome,https://beta.clinicaltrials.gov/study/NCT01901549,ACSRD,UNKNOWN,NO,Acute Coronary Syndrome|Arterial Hypertension,PROCEDURE: Renal denervation|DRUG: Metoprolol|DRUG: Lisinopril,"cardiovascular death, 1 year|myocardium infarction, 1 year|stroke, 1 year|repeat revascularization, 1 year","blood pressure changes, 1 year|CCS and NYHA, 1 year|heart rhythm disturbances, 1 year|intima-media index, 1 year|IVS thickness, 1 year|restenosis, 1 year|diastolic disfunction, 1 year",,Meshalkin Research Institute of Pathology of Circulation,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",AMIRD,
NCT01663805,"Effects of the Use of ""de Novo"" Everolimus in Renal Tranplant Population",https://beta.clinicaltrials.gov/study/NCT01663805,,UNKNOWN,NO,Delayed Function of Renal Transplant,DRUG: Everolimus,"Molecular profile of cytokines, To characterize the molecular profile of cytokines in kidneys obtained from deceased donors such as ""standard"" (SCD) and extended criteria (ECD) in biopsies taken before and after transplantation and to evaluate the effect of treatment with everolimus (EVL) in the expression of these molecules., 12 months","Pattern of cytokines with DGF, cold ischemia time, episodes of acute rejection, To correlate the pattern of cytokines with DGF, cold ischemia time, episodes of acute rejection and patient and graft survival, 12 months",,MARIO ABBUD FILHO,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CRAD001ABR21T,
NCT05222191,Spironolactone in CKD Enabled by Chlorthalidone: PILOT,https://beta.clinicaltrials.gov/study/NCT05222191,SPICE PILOT,RECRUITING,NO,Renal Insufficiency|Chronic Hypertension,DRUG: Spironolactone|DRUG: Chlorthalidone|DRUG: Placebo,"Change in Systolic Automated Office Blood Pressure from baseline to 12 weeks between arms, Baseline to 12 Weeks","Change in logarithmically transformed albumin/creatinine ratio from baseline to 12 weeks between arms, Baseline to 12 Weeks",,Indiana Institute for Medical Research,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",12672,
NCT01095939,Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia,https://beta.clinicaltrials.gov/study/NCT01095939,RPPEC,COMPLETED,NO,Renal Alteration,DRUG: Placebo|DRUG: Benazepril hydrochloride,"microalbuminuria excretion rate (spot or 24h), Baseline; 1 week + 24 weeks after treatment start|eGFR, Baseline; 1 week + 24 weeks after treatment start","Filtration fraction %, Baseline; 1 week + 24 weeks after treatment start|24h Ambulatory Blood Pressure, Mean; diurnal; nocturnal, Baseline; 1 week and 24 weeks after treatment start|Effective Renal Plasma Flow, Baseline; 1 week and 48 weeks after treatment start|Adverse Events, From signature of informed consent until last follow-up visit (36 months after treatment start)",,"University Hospital, Geneva",,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",09-136,
NCT04971720,PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis,https://beta.clinicaltrials.gov/study/NCT04971720,PRECISION-BP,RECRUITING,NO,Obesity|Cardiovascular Diseases|Hypertension|Nocturnal Blood Pressure|Natriuretic Peptides|Renin-Angiotensin-Aldosterone System,DRUG: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|DRUG: Valsartan 80 mg Oral Tablet,"Change in mean nocturnal systolic blood pressure, Change in mean nocturnal systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention.","Change in percent nocturnal dipping blood pressure, Change in percent nocturnal dipping blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention.|Change in 24-hour mean systolic blood pressure, Change in 24-hour mean systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention.|Change in 24-hour mean diastolic blood pressure, Change in 24-hour mean diastolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention.|Change in mean daytime systolic blood pressure, Change in mean daytime systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in mean daytime diastolic blood pressure, Change in mean daytime diastolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in mean nocturnal diastolic blood pressure, Change in mean nocturnal diastolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention.|Change in the daytime, nocturnal, and total urinary excretion parameters (Urine Sodium, Urine Potassium, Urine Creatinine, Urine Albumin)., Change in the daytime, nocturnal, and total urinary excretion parameters (Urine Sodium, Urine Potassium, Urine Creatinine, Urine Albumin) will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in 24-hour, daytime, and nocturnal ANP, BNP, NTproBNP, and renin levels, Change in 24-hour, daytime, and nocturnal ANP, BNP, NTproBNP, and renin levels will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in 24-hour, daytime, and nocturnal MRproANP levels, Change in 24-hour, daytime, and nocturnal MRproANP levels will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in 24-hour, daytime, and nocturnal Aldosterone levels, Change in 24-hour, daytime, and nocturnal Aldosterone levels will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in rhythm parameters (mesor, amplitude, and phase) for ANP, BNP, NTproBNP, renin, and melatonin rhythms., Change in rhythm parameters (mesor, amplitude, and phase) for ANP, BNP, NTproBNP, renin, and melatonin rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in rhythm parameters (mesor, amplitude, and phase) for MRproANP., Change in rhythm parameters (mesor, amplitude, and phase) for MRproANP will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in rhythm parameters (mesor, amplitude, and phase) for aldosterone rhythms., Change in rhythm parameters (mesor, amplitude, and phase) for aldosterone rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in rhythm parameters (mesor, amplitude, and phase) for cortisol rhythms., Change in rhythm parameters (mesor, amplitude, and phase) for cortisol rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention|Change in rhythm parameters (mesor, amplitude, and phase) for systolic BP, and diastolic BP rhythms., Change in rhythm parameters (mesor, amplitude, and phase) for systolic BP, and diastolic BP rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention",,University of Alabama at Birmingham,,"ADULT, OLDER_ADULT",PHASE2|PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",IRB-300007789,
NCT01932450,Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control,https://beta.clinicaltrials.gov/study/NCT01932450,RAFALE,UNKNOWN,NO,Autosomal Dominant Polycystic Kidney Disease|Hypertension,PROCEDURE: renal sympathetic denervation|DRUG: antihypertensive drugs,"office-based measurements of systolic blood pressure, Between-group change in average office-based measurements of systolic blood pressure from baseline to 12 months after randomization and One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation., baseline and 12 months (day 360Â±14)","24-hour systolic blood pressure by ambulatory blood pressure monitoring (ABPM), Change in average 24-hour systolic blood pressure by ambulatory blood pressure monitoring (ABPM) from baseline to 12 month., baseline and 12 months (day 360Â±14)|Incidence of office systolic blood pressure reduction, Incidence of office systolic blood pressure reductions of â‰¥10, â‰¥15 and â‰¥20 mm Hg from baseline to 12 month., baseline and 12 months (day 360Â±14)|office diastolic blood pressure, Change in office diastolic blood pressure from baseline to 12 months., baseline and 12 months (day 360Â±14)|number and dosage of blood pressure tablets, Change in number and dosage of blood pressure tablets from baseline to 12 months., baseline and 12 months (day 360Â±14)|estimated Glomerular Filtration Rate(eGFR), Change in estimated Glomerular Filtration Rate(eGFR) from baseline to 12 months., baseline and 12 months (day 360Â±14)|albuminuria, Change in albuminuria from baseline to 12 months., baseline and 12 months (day 360Â±14)|total kidney volume (TKV), Change in total kidney volume (TKV) from baseline to 12 months, baseline and 12 months (day 360Â±14)|pain, Change in pain related to cystic kidneys from baseline to 12 months., baseline and 12 months (day 360Â±14)|procedure-related complications at femoral puncture site, Occurrence of procedure-related complications at femoral puncture site (hematoma, arteriovenous fistula, pseudoaneurysma)., up to 1 year (after radiofrequency ablation)|Renal artery lesion, Renal artery lesion (perforation or dissection)., up to 1 year (after radiofrequency ablation)|New renal artery stenosis, New renal artery stenosis \>70%, determined by MRI within 12 months of randomization., up to 1 year (after radiofrequency ablation)|Embolic events, Embolic events., up to 1 year (after radiofrequency ablation)|hypotension, Episodes of hypotension., up to 1 year (after radiofrequency ablation)|hypertension., Episodes of hypertension., up to 1 year (after radiofrequency ablation)|acute kidney injury, Acute deterioration of renal function, up to 1 year (after radiofrequency ablation)|total cyst volume (TCV), Change in total cyst volume (TCV) from baseline to 12 months, baseline and 12 months (day 360Â±14)",,Mei changlin,,ADULT,PHASE2,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CZKIPLA-ADPKD-001,
NCT00345150,Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls,https://beta.clinicaltrials.gov/study/NCT00345150,,COMPLETED,NO,Hypertension,DRUG: Ng-monomethyl-L-arginine (drug),,,,Regional Hospital Holstebro,,ADULT,PHASE1,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE|Primary Purpose: ,MED.RES.HOS.1995.01.JNB,
NCT01247090,Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease,https://beta.clinicaltrials.gov/study/NCT01247090,,COMPLETED,YES,Hypertension|End Stage Renal Disease,DRUG: Vasopressin - Very Low Dose|DRUG: Vasopressin - Low Dose|DRUG: Placebo Comparator,"Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period, This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure., Baseline and Two Weeks",,,Columbia University,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",AAAE0454 - pilot,Study Protocol and Statistical Analysis Plan
NCT05700903,Contributions to Hypertension With Androgen Deprivation Therapy,https://beta.clinicaltrials.gov/study/NCT05700903,ARCH,NOT_YET_RECRUITING,NO,Androgen Deprivation Therapy|Prostate Cancer|Hypertension|Autonomic Dysfunction|Renal Disease,DRUG: Gonadotropin-Releasing Hormone Agonist|DRUG: Androgen receptor inhibitor|DRUG: Placebo,"Change in Cardiovagal Baroreflex Sensitivity, The change in cardiovagal baroreflex sensitivity will be assessed the modified Oxford procedure, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in blood pressure reactivity to the cold pressor test, The change in blood pressure will be assessed from quiet rest to sympathetic activation using the cold pressor test, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in exercise pressor reflex, The change in blood pressure will be assessed from quiet rest to isometric handgrip exercise, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in ambulatory blood pressure variability, Ambulatory blood pressure variability will be determined from 24-hour ambulatory blood pressure monitoring., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in beat-to-beat blood pressure variability, Beat-to-beat blood pressure variability will be using finger photoplethysmography measured in the laboratory., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in renal vascular resistance, Renal blood flow will be determined using ultrasound and blood pressure will be determined using finger photoplethysmography. These measures will be used to estimate renal vascular resistance., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in Renal dysfunction biomarkers, Neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule (KIM)-1, interleukin (IL)-18, and vanin-1 will be quantified in urine using commercially available assay kits. Concentrations will be normalized to urinary flow rate., Before and after 9 weeks of androgen deprivation therapy or placebo","Change in sympathetic baroreflex sensitivity, Changes in muscle sympathetic nerve activity in response to changes in blood pressure will be assessed using the modified Oxford procedure, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in Sympathetic reactivity, The change in muscle sympathetic nerve activity will be assessed from quiet rest to sympathetic activation using the cold pressor test., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in glomerular filtration rate, Glomerular filtration rate and renal plasma flow will be calculated by iohexol (Omnipaque 300, GE Healthcare) clearance technique. Plasma and urine iohexol and p-aminohippurate clearance will be measured on a High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA)., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in renal plasma flow, Renal plasma flow will be calculated by p-aminohippurate (Basic Pharma) clearance techniques. Plasma and urine p-aminohippurate clearance will be measured on a High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA)., Before and after 9 weeks of androgen deprivation therapy or placebo","Change in Inflammation, Proteomic analysis of inflammatory cascade proteins will be quantified in plasma samples., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in Oxidative stress, Whole blood reactive oxygen species will be measured in from venous blood samples using electron paramagnetic resonance spectroscopy, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in Body composition, Descriptive variable total body fat mass (for screening and to document any changes with the intervention), Before and after 9 weeks of androgen deprivation therapy or placebo","University of Colorado, Denver",,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",22-2201,
NCT02376075,"Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria",https://beta.clinicaltrials.gov/study/NCT02376075,,COMPLETED,NO,Arterial Hypertension|Albuminuria,DRUG: Linagliptin|DRUG: Placebo,"Albumin/Creatinine Ratio (UACR) in 24h urine change between Baseline and Visit 4, up to 14 weeks of study drug intake","24 hour urinary sodium excretion change between Baseline and Visit 4, after 14 weeks of study drug intake|Fasting cystatin C change between Baseline and V4, up to 14 weeks of study drug intake|Fasting cGMP change between Baseline and Visit 4, after 14 weeks of study drug intake|Fasting serum ADMA change between Baseline and V4, up to 14 weeks of study drug intake|Fasting hsCRP change between Baseline and Visit 4, up to 14 weeks of study drug intake|Fasting TGF-ÃŸ1 change between Baseline and Visit 4, after 14 weeks of study drug intake|Retinal endothelial function change between Baseline and Visit 4, up to 14 weeks of study drug intake|Retinal microvascular blood flow change between Baseline and Visit 4, up to 14 weeks of study drug intake|24h blood pressure measurements change between Baseline and Visit 4, up to 14 weeks of study drug intake|HbA1c change between Baseline and Visit 4, up to 14 weeks of study drug intake|Body weight change during study participation, up to 14 weeks of study drug intake|Adverse events during study participation, up to 14 weeks of study drug intake",,ikfe-CRO GmbH,Ikfe GmbH|MLM Medical Labs GmbH,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: ",ikfe-Lina-003|2012-004300-35,
NCT01409408,Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan,https://beta.clinicaltrials.gov/study/NCT01409408,,WITHDRAWN,NO,Hypertension|Diabetes Mellitus,DRUG: Aliskiren|DRUG: Amlodipine,"Vascular stiffness, Vascular stiffness will be measured by pulse wave velocity and augmentation index and compared between anlodipine and aliskiren., 8 weeks|Endothelial function, Access endothelial function by peripheral arterial tonometry and brachial flow-mediated vasodilation and compare it between anlodipine and aliskiren., 8 weeks|Renin activity and concentration, Access plasma renin activity and concentration and compare it between anlodipine and aliskiren., 8 weeks","Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring, Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring, 8 weeks|Assess drugs effects in renin-angiotensin-aldosterone system (RAAS) and correlate it to renin concentration/mass and plasmatic renin activity, Assess drugs effects in RAAS and correlate it to renin concentration/mass and plasmatic renin activity, 8 weeks|Correlation of drug effects and uric acid plasmatic concentration, Correlation of drug effects and uric acid plasmatic concentration, 8 weeks|Correlation of drug effects and glomerular filtration rate, Correlation of drug effects and glomerular filtration rate, 8 weeks|Correlation of drug effects and microalbuminuria, Correlation of drug effects and microalbuminuria, 8 weeks|Correlation of drug effects and left ventricular mass and function (systolic and diastolic), Correlation of drug effects and left ventricular mass and function (systolic and diastolic), 8 weeks",,Hospital Universitario Pedro Ernesto,Novartis,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",CAALIDH,
NCT01090752,Renal and Hormonal Effects of Pioglitazone,https://beta.clinicaltrials.gov/study/NCT01090752,,COMPLETED,YES,Diabetes|Hypertension,DRUG: Pioglitazone|DRUG: Metformin,"Effects of Pioglitazone on Renal Hemodynamics, At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF, 2008|Effects of Pioglitazone on Sodium and Lithium Clearances, At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances, 2007|Effects of Pioglitazone on 24h Blood Pressure Control, 24 hour blood pressure measurements were performed after each treatment/diet phase, march 2009","Effects of Pioglitazone on Salt Sensitivity, 2009",,"University Hospital, Geneva",University of Lausanne Hospitals,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",FDAAA,
NCT01275352,CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression,https://beta.clinicaltrials.gov/study/NCT01275352,,WITHDRAWN,NO,Hypertension,DRUG: Eplerenone|DRUG: placebo,"Change in LV mass index (g/m2) in ClC-Ka Gly/Gly83 patients and ClC-Ka Gly/Gly83 patients, 12 months","Change in LV relative wall thickness, 6 and 12 months|Change in N-terminal pro-brain natriuretic peptide (NT-proBNP), 6 and 12 months|Change in LV mass index (g/m2), 6 months",,Washington University School of Medicine,University of Pennsylvania,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CLNCKA-1,
NCT00221845,Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients,https://beta.clinicaltrials.gov/study/NCT00221845,ESCAPE,COMPLETED,NO,Children|Chronic Renal Failure|Hypertension|Acquired Kidney Disease|Congenital Kidney Disease,DRUG: ACE Inhibition|DRUG: Intensified Blood Pressure Control|DRUG: Add-on Angiotensin Receptor Blockade,"Time interval to renal 'loss' as defined by an absolute decrease in creatinine clearance by 50 % or attainment of renal replacement therapy., two-monthly","Effect of treatment on urinary protein excretion, two-monthly|Effect of treatment on blood pressure, two-monthly|Safety of treatment, initially weekly, than two-monthly",,Heidelberg University,European Commission|Boehringer Ingelheim|Baxter Healthcare Corporation|Aventis Pharmaceuticals,"CHILD, ADULT",PHASE3,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,QLRT-2001-00908,
NCT00151827,Olmesartan Medoxomil in Hypertension and Renal Impairment,https://beta.clinicaltrials.gov/study/NCT00151827,,COMPLETED,NO,Essential Hypertension|Renal Impairment,DRUG: Olmesartan medoxomil|DRUG: Losartan|DRUG: Furosemide oral tablets,"Change in mean sitting diastolic blood pressure (dBP), assessed by conventional blood pressure measurements after 12 weeks of treatment, Baseline to 12 weeks","Change in mean sitting diastolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment;, Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks|Change in mean sitting systolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment;, Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks|Response to treatment after 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks of treatment;, Response to treatment = mean sitting diastolic blood pressure less than or equal to 90 mmHg or reduction greater than or equal to 10 mmHg, Baseline to 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks|Changes in creatinine clearance after 12 and 52 weeks of treatment, changes in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment;, Baseline to 12 and 52 weeks|Changes in serum creatinine after 12 and 52 weeks of treatment, Baseline to 12 and 52 weeks|Rate of patients per dose level after 12 and 52 weeks of treatment, Baseline to 12 and 52 weeks|Change in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment, Baseline to 4, 12, 24, 36 and 52 weeks",,Sankyo Pharma Gmbh,,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",SE-866/43,
NCT04364139,African American Study of Kidney Disease and Hypertension,https://beta.clinicaltrials.gov/study/NCT04364139,AASK,COMPLETED,NO,Hypertensive Nephrosclerosis|Chronic Renal Insufficiency,OTHER: MAP goal less than or equal to 92 mm Hg|OTHER: MAP goal 102-107 mm Hg|DRUG: Ramipril|DRUG: Amlodipine|DRUG: Metoprolol,"Rate of change in GFR, GFR slope was determined separately during the first 3 months after randomization (acute phase) and during the remainder of follow-up (chronic phase), Up to 3 years","Time to 50% reduction in GFR, ESRD, or death up to 3 years, Time from randomization to any of the following (1) confirmed reduction in GFR by 50% or by 25 mL/min per 1.73 m\^2, (2) end stage renal disease (ESRD), or (3) death, Up to 3 years|Change in proteinuria, Change in proteinuria from baseline to the end of follow-up, Baseline to 3 years|Time to 50% reduction in GFR, ESRD, or death up to 10 years, Time from randomization to any of the following (1) confirmed reduction in GFR by 50% or by 25 mL/min per 1.73 m\^2, (2) end stage renal disease (ESRD), or (3) death, Up to 10 years",,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),The Cleveland Clinic,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",AASK U01DK048648|U01DK048648,
NCT00234871,"TarkaÂ® vs. LotrelÂ® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)",https://beta.clinicaltrials.gov/study/NCT00234871,TANDEM,COMPLETED,NO,Hypertension|Diabetes|Proteinuria,DRUG: trandolapril/verapamil|DRUG: Lotrel (amlodipine/benazepril),"Changes in urinary albumin:creatinine ratio, 36 weeks","Changes in blood pressure (BP), BP control, ABPM, proteinuria, GFR lipid parameters, glycemic control, quality of life, CRP, oxidative stress markers, clinical safety labs and adverse events., 36 weeks",,Abbott,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,M03-599,
NCT00288171,Allopurinol for Renal Transplant Associated Hypertension in Children,https://beta.clinicaltrials.gov/study/NCT00288171,,WITHDRAWN,NO,Hypertension|Renal Transplant,DRUG: Placebo|DRUG: Allopurinol,"Systolic Blood Pressure, 2 months","Serum Creatinine, 2 months|urinary bradykinin, 2 months|urinary nitrates, 2 months",,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Baylor University,"CHILD, ADULT",PHASE1|PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",DK64587-POST (terminated)|K23DK064587,
NCT00657306,Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function,https://beta.clinicaltrials.gov/study/NCT00657306,AILD,UNKNOWN,NO,Cirrhosis With Ascites,DRUG: hydrocortisone|DRUG: dextrose solution 5%,"renal function, 10 days",,,"University of Turin, Italy",,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,AILD,
NCT01131845,The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil,https://beta.clinicaltrials.gov/study/NCT01131845,,COMPLETED,NO,Pulmonary Arterial Hypertension|Renal Dysfunction,DRUG: UT-15C SR (treprostinil diethanolamine),"Treprostinil pharmacokinetics in volunteers with varying degrees of renal function following a single oral dose of a 1 mg treprostinil diethanolamine sustained release., 48hrs post dose (60 hours for ESRD)",,,United Therapeutics,,"ADULT, OLDER_ADULT",PHASE1,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,TDE-PH-120,
NCT01885559,HALT Progression of Polycystic Kidney Disease Study B,https://beta.clinicaltrials.gov/study/NCT01885559,HALT PKD B,COMPLETED,YES,"Kidney, Polycystic",DRUG: Lisinopril|DRUG: Telmisartan|DRUG: Placebo,"Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death., Patients followed for 5-8 years with average of 6.5 years follow up","Albuminuria, Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years., up to 8 years (annually assessed)|Aldosterone, Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years., up at 8 years (annually assessed)|Hospitalizations, Hospitalization for any cause, up to 8 years|Cardiovascular Hospitalizations, Cause-specific hospitalizations (cardiovascular), up to 8 years|Quality of Life Physical Component Summary, Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years., up to 8 years (annually assessed)|Quality of Life Mental Component Summary, Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years., up to 8 years (annually assessed)|Back or Flank Pain, Report of back or flank pain since the last visit (yes or no), 48 months",,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Boehringer Ingelheim|Merck Sharp & Dohme LLC|Polycystic Kidney Disease Foundation|University of Pittsburgh|Washington University School of Medicine,"CHILD, ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",HALT PKD B|U01DK062401|U01DK082230,
NCT00446459,Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.,https://beta.clinicaltrials.gov/study/NCT00446459,,COMPLETED,YES,"Kidney Failure, Chronic|Diabetic Nephropathies|Glomerulonephritis, IGA|Hypertension, Renal",DRUG: mycophenolate mofetil (CellCept),"The Number of Subjects With a 10% Decrease in PRA Level at Month 8., Enrollment to month 8","The Number of Subjects With Significant Infections up to Month 12., The number of infections while on-study up to month 12. Subjects who's PRA decreased by 10% at month 8 and who went on to the Mycophenolate mofetil + Rituximab study were followed to month 8. Those subjects who stayed on the Mycophenolate mon-therapy study were observed for infection over 12 months or until they seperated from the study., From enrollment to month 12.|The Number of Kidney Transplant up to 12 Months., The number of kidney transplants up to month 12. Subjects who's PRA decreased by 10% at month 8 and who went on to the Mycophenolate mofetil + Rituximab study were followed to month 8. Those subjects who stayed on the Mycophenolate mon-therapy study were observed for infection over 12 months or until they seperated from the study., Enrollment to month 8 or month 12 post enrollment.|The Number of Pariticpants With a White Blood Cell Count Below 2.0 Thousand (Low) or Total IgG/IgM Titers Below Range (620-1490 mg/dL)., The number of subjects with adverse hematologic effects with MMF while on-study. Subjects who's PRA decreased by 10% at month 8 and who went on to the Mycophenolate mofetil + Rituximab study were followed to month 8. Those subjects who stayed on the Mycophenolate mon-therapy study were observed for hematologic effects up to 12 months., Enrollment to month 12.|The Number of Transplants With a Negative Crossmatch at Transplant., The number negative crossmatch transplants up to month 12. Positivie crossmatch transplant carries a higher risk for rejection. Subjects who's PRA decreased by 10% at month 8 and who went on to the Mycophenolate mofetil + Rituximab study were followed to month 8. Those subjects who stayed on the Mycophenolate mon-therapy study were observed for negative crossmatch transplants to 12 months., Number of Transplants with a Negative Crossmatch.",,University of Washington,Hoffmann-La Roche,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,24223-A|03-7915-A,
NCT01380717,Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD),https://beta.clinicaltrials.gov/study/NCT01380717,RenVas,COMPLETED,NO,Chronic Kidney Insufficiency|Hypertension|Vasodilation,"DRUG: Beta-blocker, ACE-inhibitor|DRUG: Calcium Channel Blockers, ACE-Inhibitor","Change in glomerular filtration rate between the two treatment arms., Measured at baseline and after 18 months of treatment","Changes in glomerular filtration rate stratified after changes in pulse wave velocity, renal vascular resistance and forearm minimal resistance at baseline and after 18 months of treatment., 18 months",,University of Aarhus,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,RenVas,
NCT01148368,A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers,https://beta.clinicaltrials.gov/study/NCT01148368,,COMPLETED,NO,Renal Impairment,DRUG: fimasartan,"pharmacokinetic characteristic of fimasartan, AUC, Cmax, Tmax, T1/2, and CL/F of fimasartan, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, 48h",,,"Boryung Pharmaceutical Co., Ltd",Seoul National University Hospital,"ADULT, OLDER_ADULT",PHASE1,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ,A657-BR-CT-113,
NCT02947750,Neurovascular Transduction During Exercise in Chronic Kidney Disease,https://beta.clinicaltrials.gov/study/NCT02947750,NeurovEx,RECRUITING,NO,"Renal Insufficiency, Chronic",DRUG: 6R-BH4|OTHER: 6R-BH4 placebo|DIETARY_SUPPLEMENT: Folic acid|OTHER: Exercise training|OTHER: Stretching|DIETARY_SUPPLEMENT: Histidine and beta-alanine supplementation|OTHER: Histidine and beta-alanine placebo,"Change in functional sympatholysis, Muscle oxygenation during exercise and sympathoexcitation will be measured., Baseline, Week 12|Change in vascular alpha 1 adrenergic responsiveness, Changes in vascular diameter in response to phenylephrine will be measured., Baseline, Week 12|Change in exaggerated pressor responses during exercise, Blood pressure and sympathetic responses during exercise will be measured., Baseline, Week 12","Renal artery resistance during exercise, Renal artery blood flow will be measured., Baseline, Week 12|Change in endothelial function, Endothelial function using peripheral arterial tonometry will be measured., Baseline, Week 12|Change in vascular stiffness, Vascular stiffness using applanation tonometry., Baseline, Week 12",,Emory University,"National Heart, Lung, and Blood Institute (NHLBI)","ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,IRB00091660|R01HL135183,
NCT02046395,Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus,https://beta.clinicaltrials.gov/study/NCT02046395,UFLC,COMPLETED,NO,Type 2 Diabetes|Hypertension,"DRUG: amlodipine, hydralazine, terazosin or hydrochlorothiazide","Change in urine microalbumin creatinine ratio, Kidney function will be assessed throughout the study to assess changes in function prior to the washout of ACE/ARB medication and reintroduction of the ACE/ARB medication., Visit 1 (screening visit and the beginning of the washout period may be combined -day -30), Visit 2 (day 30 of the washout period and the beginning of the test period), Visit 3 (day 30 of the test period), Visit 4 day (60) and Visit 5 (day 90)","Change in the level of Urinary Free Light Chains, In relation to kidney function and washout/reintroduction of ACE/ARB medication the level of urinary free light chains will be assessed., Visit 1 (screening visit and the beginning of the washout period may be combined -day -30), Visit 2 (day 30 of the washout period and the beginning of the test period), Visit 3 (day 30 of the test period), Visit 4 day (60) and Visit 5 (day 90)",,Tulane University School of Medicine,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,258683,
NCT01208714,Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study),https://beta.clinicaltrials.gov/study/NCT01208714,METRAS,UNKNOWN,NO,Renal Artery Stenosis,DRUG: Optimal medical therapy|PROCEDURE: revascularization,"Glomerular filtration rate in the ischemic kidney after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment., The Primary Objective of the study is to determine if revascularization by means of PTRAS is superior or equivalent to optimal medical treatment for preserving glomerular filtration rate in the ischemic kidney as assessed by 99TcDTPA sequential renal scintiscan, 24 months","Lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment., One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment., 1, 3, 6, 12, 24, 36, 48 and 60 months|Preserving overall renal function after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment., One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in preserving overall renal function, as assessed by total estimated GFR, the reciprocal of serum creatinine, and indexes of Ca2+ and PO43- metabolism., 1, 3, 6, 12, 24, 36, 48 and 60 months|Regression of damage in the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment., One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in tregressing damage of the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness., 1, 3, 6, 12, 24, 36, 48 and 60 months",,University Hospital Padova,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GPR-METRAS,
NCT05208814,a Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients With Renal Insufficiency and Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT05208814,,COMPLETED,NO,Pulmonary Arterial Hypertension|Erectile Dysfunction,DRUG: TPN171H single dose,"Area under the curve (AUC), Area under the curve (AUC) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Time to maximum plasma concentration (Tmax), Time to maximum plasma concentration (Tmax) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Maximum plasma concentration (Cmax), Maximum plasma concentration (Cmax) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Terminal half-life (t 1/2), Terminal half-life (t 1/2) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours|Apparent distribution volume (Vd), Apparent distribution volume (Vd) for plasma and urine following a single dose of TPN171H in subjects with renal mpairment and healthy subjects., 72 hours or 120 hours after dosing|Clearance rate (CL), Clearance rate (CL) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Oral bioavailability (F), Oral bioavailability (F) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Adverse events, Number of Participants With treatment-related Adverse Events and Serious Adverse Events., From administration of study drug through 8 days after administration of study drug",,,Vigonvita Life Sciences,"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","ADULT, OLDER_ADULT",PHASE1,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,TPN171H-10,
NCT01349114,Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects,https://beta.clinicaltrials.gov/study/NCT01349114,,TERMINATED,YES,Diabetes|Pre-hypertension|Hypertension,DRUG: aliskiren 300 mg once daily|DRUG: Placebo/sugar pill,"Change in Flow-mediated Dilation, Flow-mediated dilation of the brachial artery assessed by ultrasound to evaluate improvement of arterial functioning by % of dilation after non-invasive occlusion, Baseline to 3 months","Mean Central Aortic Pressure at 3 Months, Baseline to 3 months after Aliskiren/PLC, reported value at 3 months after start of study of central aortic pressure assessed by non-invasive applanation tonometry ( SphygmoCor, Atcor), 3 months after start of study",,University of Alabama at Birmingham,Novartis,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",F110124007,
NCT02527837,The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects,https://beta.clinicaltrials.gov/study/NCT02527837,HYCA,UNKNOWN,NO,Hypertension,DRUG: Sodium nitrite|DRUG: Sodium chloride,"Fractional urinary sodium excretion (FENa), 1 day","Peripheral (brachial) blood pressure, Measured by oscillometric sphygmomanometer, 1 day|Central aortic systolic blood pressure (CASP), Measured by tonometric pulse wave analysis. Device BPro from HealthSTATS international, Singapore, 1 day|Plasma concentration of nitrite and nitrate (NOx), 1 day|Urinary excretion of nitrite and nitrate (NOx), 1 day|Glomerular filtration rate, 1 day|Proximal sodium transport (Estimated by lithium clearance), Estimated by lithium clearance, 1 day|Free water clearance, 1 day|Urinary excretion of cyclic guanosine monophosphate (cGMP), 1 day|Urinary excretion of epithelial sodium channels (ENaC), 1 day|Urinary excretion of aquaporin 2 water channels (AQP2), 1 day|Plasma concentration of renin (PRC), 1 day|Plasma concentration of angiotensin II (ANG2), 1 day|Plasma concentration of aldosterone, 1 day|Plasma concentration of atrial natriuretic peptide (ANP), 1 day|Plasma concentration of brain natriuretic peptide (BNP), 1 day|Plasma concentration of cyclic guanosine monophosphate (cGMP), 1 day|Plasma concentration of endothelin, 1 day|Plasma concentration of vasopressin (AVP, ADH), 1 day",,Erling Bjerregaard Pedersen,,"ADULT, OLDER_ADULT",PHASE1,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,JBR-1-2014,
NCT00140907,"ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)",https://beta.clinicaltrials.gov/study/NCT00140907,,COMPLETED,NO,High Blood Pressure,DRUG: losartan potassium|DRUG: Comparator: Placebo,"Incidence of chronic allograft nephropathy, 24 months post treatment",,,Organon and Co,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",0954-222|MK0954-222|2005_053,
NCT00498433,Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension,https://beta.clinicaltrials.gov/study/NCT00498433,,TERMINATED,YES,Hypertension|Abdominal Obesity,DRUG: Aliskiren|DRUG: Amlodipine|DRUG: Placebo of Aliskiren|DRUG: Placebo of amlodipine,"Part 1: Aliskiren Concentrations From Interstitial Fluid (Microdialysis)at the End of Aliskiren Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentrations on the last day of the aliskiren treatment periods (Day 42)., Day 42|Part 1: Amlodipine Concentrations From Interstitial Fluid (Microdialysis) at the End of Amlodipine Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentration on the last day of the amlodipine treatment periods (Day 98)., Day 98|Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Aliskiren Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 42|Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Amlodipine Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 98|Part 1: Aliskiren Concentrations From Tissue at the End of Aliskiren Treatment Period, Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine aliskiren concentration. Tissue biopsy samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42)., Day 42|Part 1: Angiotensin II Levels From Tissue During Aliskiren Treatment Period, Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine Ang II concentration., Day 42|Part 1: Renin Activity and Concentrations From Adipose and Skeletal Tissues During Aliskiren Treatment Period, Day 42|Part 1: Aliskiren Concentrations From Plasma at the End of Aliskiren Treatment Period, Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42)., Day 42|Part 1: Amlodipine Concentrations From Plasma at the End of Amlodipine Treatment Period, Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the amlodipine treatment periods (Day 98)., Day 98|Part 1: Angiotensin II Levels in Plasma During Aliskiren Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 42|Part 1: Angiotensin II Levels in Plasma During Amlodipine Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 98|Part 1: Renin Concentrations From Plasma During Aliskiren Treatment Period, Renin concentrations from plasma were measured as: plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration)., Day 42|Part 1: Renin Concentrations From Plasma During Amlodipine Treatment Period, Renin concentrations from plasma were measured as plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration)., Day 98|Part 1: Renin Activity From Plasma During Aliskiren Treatment Period, Plasma Renin activity (PRC) was measured by a trapping PRA (tPRA) assay., Day 42|Part 1: Renin Activity From Plasma During Amlodipine Treatment Period, Plasma renin activity (PRC) was measured by a trapping PRA (tPRA) assay., Day 98|Part 2: Change From Baseline in Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Double Blind Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Change From Baseline in Plasma Angiotensin II Levels During Double Blind Treatment Period, Plasma Ang II was measured prior to and 1 hour after the Insulin modified-frequently sampled intravenous glucose tolerance test (IM-FSIGT) during placebo treatment (Days 14) and active treatment(Day 98)., Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Plasma Renin Activity (PRA) Concentration During Double Blind Treatment Period, Day 98|Part 2: Plasma Renin Concentration (PRC) Levels During Double Blind Treatment Period, Day 98","Part 2: Microdialysis Metabolic Analytes in Response to Insulin Modified Frequently Sampled Intravenous Glucose Test [IM-FSIGT]for Each Tissue (Adipose or Skeletal Muscle), Day 14 and Day 98|Part 2: Change From Baseline in Official Blood Pressure, Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Renin Activity and Concentration of Aliskiren and Amlodipine in Fat and Skeletal Muscle Interstitial Fluid, Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Change From Baseline in Peripheral Insulin Sensitivity in Response to Insulin Modified Frequently Sampled Intravenous Glucose Test [IM-FSIGT]for Each Tissue (Adipose or Skeletal Muscle), Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Change From Baseline in Mitochondrial Mass in Subcutaneous Fat and Skeletal Muscle (Tissue Biopsies), Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Number of Participants With Reported Any Adverse Events, Serious Adverse Events and Death, 98 days",,Novartis,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CSPP100A2238,
NCT01284114,Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients,https://beta.clinicaltrials.gov/study/NCT01284114,,COMPLETED,YES,Hypertension|Chronic Kidney Disease,DRUG: Aliskiren,"The Change of Blood Pressure, The change of systolic blood pressure and diastolic blood pressure, baseline and 6 month|The Change of Heart Function Confirmed by Echocardiograph, Left ventricular ejection fraction (LVEF)were measured by echocardiogram at baseline and 6 month. Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month., baseline and 6 month|The Change of BNP, Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month., baseline and 6month|The Change of eGFR, eGFR was calculated at baseline and at 6 month using a modified version of the Modification of Diet in Renal Disease (MDRD) formula of the Japanese Society of Nephrology as follows: eGFR (ml/min/1.73 m2) = 194 Ã— age-0.287 Ã— serum creatinine-1.094 (multiplied by 0.739 for females)., baseline and 6 month|The Change of Urine Albumin/ Creatinine Ratio (UACR)., The UACR was measured at baseline, Week12 and Week24, baseline and 6 months","The Change of Oxidative Stress Markers Confirmed by Plasma Level of 8-OHdG and d-ROM, 6 months",,Jichi Medical University,,OLDER_ADULT,PHASE4,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,JMU-N1,
NCT01734096,Renal Response to Lower Body Negative Pressure in Pre-hypertensive States,https://beta.clinicaltrials.gov/study/NCT01734096,,COMPLETED,NO,Hypertension|Obesity|White Coat Hypertension|Resistant Hypertension,OTHER: Lower body negative pressure (LBNP)|DRUG: Candesartan cilexetil,"sodium excretion, sodium excretion will be compared to control group (healthy volunteers) after one hour of lower negative pressure. The protocol includes 2 hours of baseline measure, one hour of lower negative pressure and 2 hours of recovery, after one hour of lower body negative pressure","glomerular filtration rate, after one hour of lower body negative pressure","renal plasma flow, after one hour of lower body negative pressure",PD Dr. GrÃ©goire Wuerzner,Swiss National Science Foundation,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",PZ00P3_121655,
NCT00140790,Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study,https://beta.clinicaltrials.gov/study/NCT00140790,,TERMINATED,NO,Hypertension,DRUG: valsartan,"Cardiovascular events, 2 years|End-stage renal dysfunction, 2 years|50% reduction of creatinine clearance, 2 years","% FS and E/A ratio, 2 years|Specific biochemical markers for cardiac or renal function, 6 months and 1 year and 2 years|% changes of creatinine clearance, 2 years|1/(serum Cr), 2 years|Serum K, 2 years|HbA1c, 2 years|U-prot/U-Cr, 2 years|Adverse drug effects, 2 years|New onset Atrial Fibrillation, 2 years",,Kumamoto University,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,CVM-RCT-2005-02,
NCT00852787,Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease,https://beta.clinicaltrials.gov/study/NCT00852787,,UNKNOWN,NO,Hypertension|Hemodialysis,DRUG: Digoxin immune fab|DRUG: Placebo,"Blood pressure, Screening, and 24-hour period after first infusion and after second infusion","Marinobufagenin levels, Screening, and after first and second infusions",,National Institute on Aging (NIA),University of Toledo Health Science Campus,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",AG0115|263-MA-707136-1,
NCT00240422,Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes,https://beta.clinicaltrials.gov/study/NCT00240422,,COMPLETED,NO,"Diabetes Mellitus, Type 2|Hypertension",DRUG: Telmisartan|DRUG: Ramipril,"Change from baseline of renal plasma flow (RPF) in response to L-NMMA infusion at the end of treatment., 9 weeks","Change from baseline of glomerular filtration rate (GFR) in response to L-NMMA infusion at the end of treatment, 9 weeks|Change from baseline of filtration fraction (FF) in response to L-NMMA infusion at the end of treatment., 9 weeks|Change from baseline of renal vascular resistance (RVR) in response to L-NMMA infusion at the end of treatment., 9 weeks|Change from baseline of RPF in response to L-arginine infusion at the end of treatment., 9 weeks|Change from baseline of GFR in response to L-arginine infusion at the end of treatment, 9 weeks|Change from baseline of FF in response to L-arginine infusion at the end of treatment., 9 weeks|Change from baseline of RVR in response to L-arginine infusion at the end of treatment., 9 weeks|Change from baseline of mean arterial pressure (MAP) and pulse rate (PR) in response to L-NMMA infusion at the end of treatment., 9 weeks|Change from baseline of MAP and PR in response to L-arginine infusion at the end of treatment., 9 weeks|Change from baseline of the laboratory parameters angiotensin II (ANG II), aldosterone, asymmetrical dimethylarginine (ADMA), L-arginine, urinary nitrate/nitrite (UNOx), and urinary albumin excretion at the end of treatment, 9 weeks|Change from baseline of the pre-L-NMMA RPF at the end of treatment, 9 weeks|Change from baseline of the pre-L-NMMA GFR at the end of treatment, 9 weeks|Change from baseline of the pre-L-NMMA FF at the end of treatment., 9 weeks|Change from baseline of the pre-L-NMMA RVR at the end of treatment., 9 weeks|Change from baseline of the urinary excretion parameters creatinine, sodium, potassium, and urea at the end of treatment., 9 weeks|Blood pressure response and control at the end of treatment, 9 weeks|Change from baseline of central blood pressure and augmentation index (by pulse wave analysis) at the end of treatment., 9 weeks|Change from baseline of RPF in response to Vitamin C infusion at the end of treatment, 9 weeks|Change from baseline of GFR in response to Vitamin C infusion at the end of treatment, 9 weeks|Change from baseline of FF in response to Vitamin C infusion at the end of treatment., 9 weeks|Change from baseline of RVR in response to Vitamin C infusion at the end of treatment., 9 weeks|Change from baseline of MAP and PR in response to Vitamin C infusion at the end of treatment., 9 weeks|Incidence of adverse events, week -2 and 9 weeks|Changes from base line in routine laboratory data at the end of the study, 9 weeks|Changes in vital signs, 9 weeks|Changes from screening in physical examination at the end of the study, - 4 weeks and 9 weeks|Changes from screening in ECG at the end of the study, - 4 weeks and 9 weeks",,Boehringer Ingelheim,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,502.398,
NCT02807987,Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment,https://beta.clinicaltrials.gov/study/NCT02807987,,COMPLETED,NO,Hypertension With Moderate Renal Impairment,DRUG: CS-3150,"Change from baseline in sitting systolic and diastolic blood pressure, Change from baseline in sitting systolic and diastolic blood pressure, Baseline to end of Week 12","Time course of systolic and diastolic blood pressure, Time course of systolic and diastolic blood pressure, Baseline to end of Week 12|Proportion of patients achieving blood pressure control, Proportion of patients achieving blood pressure control, Baseline to end of Week 12",,"Daiichi Sankyo Co., Ltd.",,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CS3150-A-J305,
NCT00553722,Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?,https://beta.clinicaltrials.gov/study/NCT00553722,,UNKNOWN,NO,Hypertension|Dialysis|Hyperaldosteronism,DRUG: Eplerenone|DRUG: Placebo,"Significant drop in blood pressure with Eplerenone when compared to placebo., days",,,Shaare Zedek Medical Center,,"CHILD, ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",1-Shavit,
NCT00283686,HALT Progression of Polycystic Kidney Disease Study A,https://beta.clinicaltrials.gov/study/NCT00283686,HALT PKD A,COMPLETED,YES,"Kidney, Polycystic",DRUG: Lisinopril|DRUG: Telmisartan|DRUG: Placebo|OTHER: Standard Blood Pressure Control|OTHER: Low Blood Pressure Control,"Study A: Percent Annual Change in Total Kidney Volume, Annual percentage change in total kidney volume as assessed by abdominal magnetic resonance imaging (MRI) at baseline, 2 years, 4 years, and 5 years follow-up., Baseline and 2-, 4- and 5-year follow-up","Kidney Function (eGFR), The estimated GFR was calculated by means of the Chronic Kidney Disease Epidemiology Collaboration equation with the use of central serum creatinine measurements., Up to 96 months (6 month assessments)|Albuminuria, Urine albumin excretion, centrally processed from 24 hour urine collection, Up to 96 months (assessed annually)|Aldosterone, Urinary aldosterone excretion, centrally processed, 24 hour urine collection, Up to 96 months (assessed annually)|Left Ventricular Mass Index, Left ventricular mass index (g/m\^2) measured by MRI, centrally reviewed and measured, 0, 24 months, 48 months, 60 months|Renal Blood Flow, renal blood flow (mL/min/1.73 m\^2) from MRI, centrally reviewed and measured. This outcome was more difficult to measure resulting in more missing data than other MRI outcomes such as total kidney volume (TKV) and left ventricular mass index (LVMI)., 0, 24 months, 48 months, 60 months|All-Cause Hospitalizations, Up to 96 months|Quality of Life Physical Component Summary, Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome), baseline, 12, 24, 36, 48, 60, 72, 84, and 96 months (assessed annually)|Quality of Life Mental Component Summary, Short Form-36 Quality of LIfe Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome), baseline, 12, 24, 36, 48, 60, 72, 84, and 96 months (assessed annually)",,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Boehringer Ingelheim|Merck Sharp & Dohme LLC|Polycystic Kidney Disease Foundation|University of Pittsburgh|Washington University School of Medicine,"CHILD, ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",HALT PKD A|U01DK062401|U01DK082230,
NCT04162366,A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.,https://beta.clinicaltrials.gov/study/NCT04162366,INSPIRE-CKD,WITHDRAWN,NO,"Hypertension|Renal Insufficiency, Chronic",DRUG: Aprocitentan 25 mg|DRUG: Placebo,"Change from Baseline to Week 4 of double-blind treatment in mean trough sitting systolic blood pressure measured by automated office blood pressure measurement., From baseline to Week 4 after treatment initiation","Change from baseline to Week 4 of double-blind treatment in mean trough sitting diastolic blood pressure measured by automated office blood pressure measurement., From baseline to Week 4 after treatment initiation|Ratio to baseline of urine albumin-to-creatinine ratio (UACR) at Week 4, Evaluated in the subgroup of participants with a UACR greater than 30 mg/g at baseline., From baseline to Week 4 after treatment initiation",,Idorsia Pharmaceuticals Ltd.,"Janssen Biotech, Inc.","ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",ID-080A305|2018-003819-22,
NCT02811055,Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin,https://beta.clinicaltrials.gov/study/NCT02811055,APHOS-02,UNKNOWN,NO,Type 2 Diabetes|Hypertension,BIOLOGICAL: Blood sampling|PROCEDURE: Blood Pressure Measurement|DEVICE: electrocardiogram|PROCEDURE: orthostatic test|DRUG: Administration of Aprepitant|DRUG: Administration of placebo,"Difference from baseline in Plasma aldosterone concentration, Plasma aldosterone concentration is analyzed, Baseline and Day 14","Difference from baseline in Plasma cortisol, Plasma cortisol concentration is analyzed, Baseline and Day 14|Difference from baseline in plasma renin, plasma renin concentration is analyzed, Baseline and Day 14|Difference from baseline in blood electrolytes measurement, blood electrolytes concentration is analyzed, Baseline and Day 14|Difference from baseline in HOMA index, Baseline and Day 14",,"University Hospital, Rouen",,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013/142/HP,
NCT05358912,Efficacy of Targeted Abdominal Perfusion Pressure in Septic Shock,https://beta.clinicaltrials.gov/study/NCT05358912,,COMPLETED,NO,Septic Shock|Septicemia|Intraabdominal Hypertension|Renal Injury,DRUG: Vasopressor Agent|DRUG: Crystalloid Solutions|PROCEDURE: Invasive Blood Pressure Monitoring|PROCEDURE: Intra-Abdominal Pressure Monitoring|OTHER: Abdominal Perfusion Pressure,"Change of the Level of Acute Kidney Injury, Kidney damage will be monitored according to the KDIGO (Kidney Disease Improving Global Outcomes) classification., up to 90 days|Mortality, Mortality in first 30 days, at 30th day of admission|Mortality, Mortality in first 90 days, at 90th day of admission",,,Bozyaka Training and Research Hospital,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,AbdominalPressure,
NCT00446251,Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant,https://beta.clinicaltrials.gov/study/NCT00446251,,COMPLETED,YES,"Kidney Failure, Chronic|Diabetic Nephropathies|Glomerulonephritis, IGA|Hypertension, Renal",DRUG: Rituximab|DRUG: Mycophenolate mofetil (MMF),"The Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months Post Rituximab Infusion., the number of subjects who experience a decrease in their Panel of Reactive Antibodies (PRA) at 6 months and 12 months post Rituximab infusion, Month 6 from start of study","The Number of Subjects Who Experience a Change From Baseline in Their Panel of Reactive Antibody (PRA) Titers at 12 Months Post Rituximab Infusion., Month 12 from start of study|The Number of Subjects With a Negative Crossmatch at the Time of Transplant., Month 12 from start of study",,University of Washington,"Genentech, Inc.","ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,25668-A|04-0927-A 05,
NCT00892892,Sympathetic Nerve Activity in Renal Failure,https://beta.clinicaltrials.gov/study/NCT00892892,SNS in CRF,WITHDRAWN,NO,Chronic Kidney Disease|Hypertension,DRUG: Rilmenidine|DRUG: Nitrendipine,"sympathetic activation for the development and progression of chronic renal failure, 3 months","effects of a sympatholytic agent on cardiovascular reactivity to various stressors, 3 months",,University of Erlangen-NÃ¼rnberg Medical School,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",Re-No. 3186,
NCT05470725,Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function,https://beta.clinicaltrials.gov/study/NCT05470725,,COMPLETED,NO,Hypertension,DRUG: CIN-107,"Maximum plasma concentration (Cmax), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Time to maximum plasma concentration (Tmax), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Area under the curve from time 0 to the time of last quantifiable plasma concentration (AUC[0-last]), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Area under the curve from time 0 to infinity (AUC[0-inf]), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Percent of AUC extrapolated, This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Terminal phase elimination half-life, This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Apparent plasma clearance (CL/F), This PK parameter will be determined for CIN-107 using plasma concentration data., up to Day 8|Apparent volume of distribution, This PK parameter will be determined for CIN-107 using plasma concentration data., up to Day 8|The cumulative amount of CIN-107 and CIN-107-M excreted in the urine (Ae), This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M), up to Day 8|Renal clearance (CLR) of CIN-107 and CIN-107-M of CIN-107 and CIN-107-M, Calculated as Ae/AUC. This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M), up to Day 8|The fraction of the dose excreted renally, This PK parameter will be calculated using the urine concentrations of CIN-107, up to Day 8|Number of patients experiencing adverse events (AEs), up to Day 11|Number of patients experiencing adverse drug reactions, up to Day 11|Number of patients experiencing serious adverse events (SAEs), up to Day 11",,,"CinCor Pharma, Inc.",,"ADULT, OLDER_ADULT",PHASE1,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CIN-107-113,
NCT00518765,Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet,https://beta.clinicaltrials.gov/study/NCT00518765,,COMPLETED,NO,Hypertension,DRUG: Aliskiren|DRUG: Aliskiren plus placebo|DRUG: Aliskiren|DRUG: Aliskiren plus placebo,"Renal plasma flow following 3 single doses of aliskiren in healthy volunteers on a low sodium(10 mEq/day)diet, baseline and hourly intervals.","Single dose application of aliskiren on renal hemodynamics and circulating markers of the renin pathway, baseline, and at 5 hours, and 24 hours post dose",,Novartis,,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,CSPP100A2318,
NCT01328769,"Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)",https://beta.clinicaltrials.gov/study/NCT01328769,,COMPLETED,YES,Hypertension,DRUG: Febuxostat|DRUG: Placebo,"Change in Renal Plasma Flow in Response to Infused Angiotensin II, Baseline to 6 weeks","Change in Endothelial Function, Endothelial function was calculated by software from the manufacturer VENDYS. The measurement was taken by using the index of area under the curve of the finger temperature recovery curve just after releasing a blood pressure cuff. The blood pressure cuff occluded blood flow for 5 minutes as compared to the temperature curve in the non-occluded arm., Baseline to 6 weeks",,Paul N. Hopkins,,ADULT,PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",42916,
NCT01172431,Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency,https://beta.clinicaltrials.gov/study/NCT01172431,,COMPLETED,NO,Hypertension|Renal Insufficiency,DRUG: Indapamide|DRUG: Hydrochlorothiazide,"renal function, Effects of indapamide SR 1.5 mg on renal function by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension., 1 year","endothelial function, Effects of indapamide SR 1.5 mg on endothelial function by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension., 1 year|blood pressure variability, Effects of indapamide SR 1.5 mg on blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension, 1 year",,West China Hospital,,OLDER_ADULT,PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,WestChinaH,
NCT01898910,Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation,https://beta.clinicaltrials.gov/study/NCT01898910,,COMPLETED,NO,Atrial Fibrillation|Hypertension,PROCEDURE: PVI+renal denervation|PROCEDURE: PVI + GP ablation|DRUG: Optimal medial therapy (OMT),"Freedom of AF or other atrial arrhythmias, 12 months",,,Meshalkin Research Institute of Pathology of Circulation,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",RDGP-031,
NCT00939588,Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients,https://beta.clinicaltrials.gov/study/NCT00939588,,COMPLETED,NO,Hypertension,DRUG: Aliskiren/ Valsartan|DRUG: Telmisartan/ Ramipril,"Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone, 56 days","Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on Plasma Renin Activity (PRA)and angiotensin II, 56 days|Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on mean sitting systolic and diastolic blood pressure, 56 days|Assess safety and tolerability of aliskiren + valsartan and ramipril + telmisartan, 56 days",,Novartis Pharmaceuticals,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",CSPV100A2225,
NCT00081731,Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions,https://beta.clinicaltrials.gov/study/NCT00081731,CORAL,COMPLETED,YES,"Atherosclerosis|Cardiovascular Diseases|Hypertension, Renovascular|Renal Artery Obstruction","DRUG: Atacand/HCT, Caduet|PROCEDURE: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)","Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy, Only the first event per participant is included in the composite, Measured at every 3 months for the first year and annually thereafter|Cardiovascular or Renal Death, Measured at every 3 months for the first year and annually thereafter|Myocardial Infarction, Measured at every 3 months for the first year and annually thereafter|Hospitalization for Congestive Heart Failure, Measured at every 3 months for the first year and annually thereafter|Stroke, Measured at every 3 months for the first year and annually thereafter|30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days, Measured at every 3 months for the first year and annually thereafter|Need for Renal Replacement Therapy, Measured at every 3 months for the first year and annually thereafter",,,Baim Institute for Clinical Research,Beth Israel Deaconess Medical Center,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,161|U01HL071556,
NCT01023373,Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy,https://beta.clinicaltrials.gov/study/NCT01023373,NITER,UNKNOWN,NO,"Atherosclerosis|Chronic Kidney Disease|Hypertension, Renovascular|Ischemic Nephropathy|Renal Artery Stenosis",DRUG: Medical treatment|PROCEDURE: PTRS|DEVICE: renal artery stent|DEVICE: renal artery stent,"Death, Initiation of dialysis therapy or either serum creatinine increase more than 20% or reduction by > 20% in estimated clearance of creatinine (with MDRD formula), 0.5, 1 and 2 years follow up plus extended 4 yrs","Systolic and diastolic blood pressure values at 0.5, 1 and 2 yrs follow up, with an extended follow up after 2 yrs, 0.5, 1 and 2 years follow up plus extended 4 yrs|Number of hypotensive drugs, 0.5, 1 and 2 years follow up plus extended 4 yrs|Results of renal scintigraphy, 0.5, 1 and 2 years follow up plus extended 4 yrs|Incidence of complications due to interventional manoeuvres, 0.5, 1 and 2 years follow up plus extended 4 yrs|Changes in the incidence of vascular complications in extra-renal districts, 0.5, 1 and 2 years follow up plus extended 4 yrs",,Azienda UnitÃ  Sanitaria Locale di Piacenza,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,388-2002,
NCT02539810,Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA),https://beta.clinicaltrials.gov/study/NCT02539810,ANDORRA,TERMINATED,NO,Hypertension|Hypertension Resistant to Conventional Therapy|Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent,"DEVICE: Renal artery Angioplasty plus stenting.|DRUG: Anti hypertensive, statin and antiplatelet medication.","Mean change in diurnal systolic blood pressure assessed by ambulatory BP monitoring (ABPM), Baseline to 6 months","Adverse events of renal artery stenting, Baseline to 12 months|Change in average 24-hour and nighttime Systolic Blood Pressure by ABPM, Baseline to 12 months|Change in average 24-hour, daytime and nighttime diastolic Blood Pressure by ABPM, Baseline to 12 months|Change in Systolic/diastolic Blood Pressure by home blood pressure monitoring, Baseline to 12 months|Change in office Systolic/diastolic Blood Pressure, Baseline to 12 months|Antihypertensive medication score, Baseline to 12 months|Detection of the drugs in urine by LC-MS/MS, Baseline to 12 months|Renal artery restenosis in patients of the stenting group assessed by duplex ultrasound and/or renal CTA, Baseline to 12 months|Adverse cardiovascular (CV) events, Baseline to 12 months|Change in plasma creatinine and eGFR, Baseline to 12 months|Clinical renal events: renal death, progressive renal insufficiency (i.e. need for dialysis), need for permanent renal replacement therapy, need of target vessel stenting in the SOMT group (number of crossovers), Baseline to 12 months",,Assistance Publique - HÃ´pitaux de Paris,"Ministry of Health, France","ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,P140914|P140914,
NCT01432106,The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome,https://beta.clinicaltrials.gov/study/NCT01432106,SAAVE,WITHDRAWN,NO,Hypertension|Metabolic Syndrome,DRUG: Aliskerin/Valsartan and Rampiril,"Mean Change in SBP from baseline to 10 weeks (2 weeks on initial dose & 6 weeks on higher dose), 2 weeks on initial dose & 6 weeks on higher dose",,,University of Michigan,Novartis Pharmaceuticals,"ADULT, OLDER_ADULT",PHASE1,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",SPP100AUS20T,
NCT00856960,The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127),https://beta.clinicaltrials.gov/study/NCT00856960,,COMPLETED,NO,Hypertension,DRUG: Aliskiren|DRUG: Aliskiren|DRUG: Comparator: Losartan|DRUG: Comparator: Placebo to Aliskiren|DRUG: Comparator: Placebo to Losartan,"change in renal plasma flow as measured by PAH clearance and on renal blood flow as measured by ASL MRI after single-dose Aliskiren, 2-5 hours post dose of study drug","change in renal plasma flow as measured by PAH clearance and on renal blood flow as measured by ASL MRI after single-dose Losartan, 2-5 hours post dose of study drug",,Merck Sharp & Dohme LLC,,ADULT,PHASE1,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",0000-127|127|2009_554,
NCT01960153,Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage,https://beta.clinicaltrials.gov/study/NCT01960153,PITCH-ER,WITHDRAWN,NO,Heart Failure|Pulmonary Hypertension,DRUG: Tadalafil|DRUG: Placebo,"Change in renal function, Between-group differences in changes from baseline in: (1a) eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and (1b) spot urine albumin-to-creatinine ratio (UACR), Baseline to 48 months|Incidence of acute kidney injury (AKI) events (clinical and subclinical), Impact of treatment on (2a) incidence of AKI events (adjudicated) based on new Kidney Disease Improving Global Outcomes criteria; and (2b) changes from baseline in the urine biomarkers of subclinical kidney injury: Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Marker 1 (KIM-1)., Baseline to 48 months","Changes in renal function stratified by diabetes/no diabetes, As for the primary outcome, measurements will be eGFR and UACR, Baseline to 48 months|Incidence of AKI events stratified by diabetes/no diabetes, As for the primary outcome, AKI events will be adjudicated and N-GAL and KIM-1 will be measured, Baseline to 48 months",,Massachusetts General Hospital,"National Heart, Lung, and Blood Institute (NHLBI)|HealthCore-NERI","ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2013P001412|R01HL119155-01A1,
NCT03115853,The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function,https://beta.clinicaltrials.gov/study/NCT03115853,,COMPLETED,YES,High Blood Pressure,DRUG: Aliskiren 150 mg|DRUG: Placebo|DRUG: HCTZ|DRUG: Aliskiren 300 mg,"Difference in Peak Plasma PAI-1 Level, baseline to 18 weeks|Difference in Mean Plasma PAI-1 Level, baseline to 18 weeks","Difference in Mean Plasma Aldosterone Levels, baseline to 18 weeks|Difference in Mean Changes in Plasma Renin Activity., baseline to 18 weeks|Difference in Mean Plasma Peak Aldosterone Levels, baseline to 18 weeks",,Vanderbilt University Medical Center,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,90738,
NCT00585442,Effects of Vitamin D on Renin Expression in Hypertensive Patients,https://beta.clinicaltrials.gov/study/NCT00585442,,TERMINATED,NO,Hypertension|Vitamin D Deficiency,DRUG: calcitriol|DRUG: Placebo,"Compare plasma renin activity (PRA) and plasma renin concentration (PRC) in hypertensive patients (JNC VII stage I) following 14 days treatment with calcitriol (1Î±, 25-[OH]2 vitamin D3) or matched placebo., 13 MONTHS (MAY 2007-JUNE 2008)","Compare mononuclear leukocyte renin transcription (mRNA) between calcitriol and matched placebo., 13 MONTHS (MAY 2007-JUNE 2008)",,University of Utah,,"ADULT, OLDER_ADULT",EARLY_PHASE1,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,22714|10151812,
NCT02832973,Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension,https://beta.clinicaltrials.gov/study/NCT02832973,ResHypOT,COMPLETED,NO,Hypertension Resistant to Conventional Therapy,"DRUG: Spironolactone|DRUG: Furosemide,|DRUG: Amiloride|DRUG: Ramipril|DRUG: Bisoprolol","Reduction of Systolic BP, diastolic BP, mean BP and pulse pressure levels will be used to compare sequential nephron blockade versus dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol, Systolic BP (mmHg), Diastolic BP (mmHg), Mean BP (mmHg) and Pulse Pressure (mmHg), Twenty weeks","Electrolytes changes: Sodium, Potassium Chlorine after 20 weeks of treatment with sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol, Sodium (reference: 135-145 mmol/L), potassium (reference: 3.5-5.0 mmol/L) and chlorine (reference: 96-106 mEq/L), Twenty weeks|Reduction of creatinine clearance after 20 weeks of treatment with sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol, Creatinine clearance (reference - Male: 97 to 137 mL/min and Female: 88 to 128 mL/min), Twenty weeks|Hypotension, Recognition of hypotension (ABPM - mmHg), Twenty weeks",,Sao Jose do Rio Preto Medical School,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SaoJoseRPU,
NCT01593787,Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction,https://beta.clinicaltrials.gov/study/NCT01593787,,COMPLETED,YES,Hypertension With Renal Dysfunction,DRUG: LCZ696,"Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death), Percentage of patients with total adverse events, serious adverse events and death were reported., 8 weeks","Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8, Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements., baseline, 8 weeks|Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 8, baseline, 8 weeks|Percentage of Participants Achieving a Successful BP Control at Week 8, A successful BP control was defined as msSBP \<130 mmHg and msDBP \<80 mmHg, 8 weeks|Percentage of Participants Achieving SBP Control at Week 8, SBP control was defined as msSBP \<130 mmHg., 8 weeks|Percentage of Participants Achieving DBP Control at Week 8, DBP control was defined as msDBP \<80 mmHg., 8 weeks|Percentage of Participants Achieving a Successful Response Rate in msSBP at Week 8, Successful response rate was defined as msSBP \<130 mmHg or a reduction of â‰¥20 mmHg from baseline, 8 weeks|Percentage of Participants Achieving a Successful Response Rate in msDBP at Week 8, Successful response rate was defined as msDBP \<80 mmHg or a reduction of â‰¥10 mmHg from baseline., 8 weeks",,Novartis Pharmaceuticals,,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CLCZ696A1304,
NCT00171353,A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure,https://beta.clinicaltrials.gov/study/NCT00171353,,COMPLETED,NO,Hypertension,DRUG: valsartan,Change from baseline in urine albumin excretion after 24 weeks|Change from baseline in an ultrasound measurement of blood flow after 24 weeks,Effect of blood pressure changes on urine albumin excretion rate and blood vessel function,,Novartis,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CVAL489ARU01,
NCT04085562,Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.,https://beta.clinicaltrials.gov/study/NCT04085562,,COMPLETED,NO,"Hypertension, Renal",DRUG: Bisoprolol Fumarate 5-10 mg|DRUG: Amlodipine 5-10 mg,"Change in Left Ventricular Mass Index, 6 months","Change in ADMA Blood level, 6 months",,Alexandria University,Damanhour University,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,201243,
NCT00140985,Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213),https://beta.clinicaltrials.gov/study/NCT00140985,,COMPLETED,NO,Renal Disorder,"DRUG: MK0954, losartan potassium/Duration of Treatment: 20 weeks|DRUG: Comparator: amlodipine / Duration of Treatment: 20 weeks",24h proteinuria,Changes in the plasma and urinary levels of TGF-beta,,Organon and Co,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",0954-213|MK0954-213|2005_058,
NCT00299832,SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction,https://beta.clinicaltrials.gov/study/NCT00299832,,COMPLETED,NO,Hypertension,DRUG: Aliskiren,Adverse events after 8 weeks,Change from baseline in mean sitting systolic blood pressure after 8 weeks|Change from baseline in mean sitting diastolic blood pressure after 8 weeks|Mean sitting systolic blood pressure is < 140 mmHg or a reduction of > 20 mmHg after 8 weeks|Mean sitting diastolic blood pressure is < 90 mmHg or a reduction of > 10 mmHg after 8 weeks|Blood pressure <140/90 after 8 weeks,,Novartis,,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CSPP100A1303,
NCT02594410,Zainidip in Renal Artery Stenosis,https://beta.clinicaltrials.gov/study/NCT02594410,,COMPLETED,NO,Hypertension,DEVICE: stent|DRUG: Aspirine|DRUG: Clopidogrel|DRUG: Lercanidipine,"Glomerular filtration rate, 12 months|Blood pressure, 12 months",,,Lee's Pharmaceutical Limited,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,Zhaoke-1503-zanidip,
NCT01755858,Effects of Intravenous Bendaviaâ„¢ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery,https://beta.clinicaltrials.gov/study/NCT01755858,EVOLVE,TERMINATED,YES,"Renal Artery Obstruction|Hypertension, Renovascular|Ischemia Reperfusion Injury",DRUG: Bendavia|DRUG: Placebo,"Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA., Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA.., Baseline (pre-PTRA) and 8 weeks post-PTRA","Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA., Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys., Baseline (pre-PTRA) and 8 weeks post-PTRA|Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA, Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys., Baseline (pre-PTRA) and 8 weeks post-PTRA|Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA, Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys, Baseline (pre-PTRA) and 8 weeks post-PTRA|Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA., Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA., Baseline (Pre-PTRA) and 8 (+4) weeks post-PTRA|Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA, Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging., Baseline (Pre-PTRA) , 27 hours post-PTRA and 8 weeks post-PTRA|Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA, Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia, 27H post PTRA and 8 weeks Post PTRA|Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA, Pre-PTRA and 27 hours post-PTRA and 8 weeks post-PTRA|Mean Change in Diastolic Blood Pressure, Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia., Pre-PTRA, immediately post-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA",,Stealth BioTherapeutics Inc.,,"ADULT, OLDER_ADULT",PHASE1|PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",SPIRI-225,
NCT02900729,Randomized Controlled Trial of Renal Denervation for Resistant Hypertension,https://beta.clinicaltrials.gov/study/NCT02900729,,UNKNOWN,NO,Hypertension,"DEVICE: Radiofrequency ablation catheter|DRUG: Amlodipine, losartan potassium and hydrochlorothiazide","Change in average 24-hour systolic blood pressure by ambulatory blood pressure monitoring from baseline, 3 months post-randomization","Incidence of achieving target blood pressure, Target blood pressure is defined as daytime ambulatory blood pressure \<135/85mmHg, nighttime ambulatory blood pressure \<120/70mmHg or average 24-hour ambulatory blood pressure \<130/80mmHg, respectively, 6 months post-randomization|Change in daytime and nighttime ambulatory systolic blood pressure from baseline, 3 months post-randomization|Change in 24 hour average, daytime and nighttime ambulatory diastolic blood pressure from baseline, 3 months post-randomization|Change in serum creatinine from baseline, 6 months post-randomization|Incidence of adverse event, Through study completion, up to 6 months","Change in 24 hour average, daytime and nighttime ambulatory systolic/diastolic blood pressure from baseline, 6 months post-randomization|Change in office systolic/diastolic blood pressure from baseline, 6 months post-randomization|Change in patient-recorded home systolic/diastolic blood pressure from baseline, 6 months post-randomization|Incidences of achieving reductions of â‰¥ 5 mmHg, â‰¥ 10 mmHg, â‰¥15 mmHg, and â‰¥ 20 mmHg in blood pressure, including ambulatory, office and home blood pressure, 6 months post-randomization|Incidences of substantially adjusting antihypertensive medications, A substantial adjustment of antihypertensive medications is defined as any changes in number of antihypertensive medications, or type of antihypertensive medications, or â‰¥ 50% dose change in any ongoing antihypertensive medications in the last two weeks., 6 months post-randomization","Shanghai WiseGain Medical Devices Co., Ltd.",,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,WiseGo-CT-1601,
NCT00190580,Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease,https://beta.clinicaltrials.gov/study/NCT00190580,,COMPLETED,NO,Chronic Kidney Disease|Hypertension,DRUG: valsartan|DRUG: Conventional antihypertensive drugs,"Course of renal and cardiac function, every month for renal function and every year for cardiac function","Doubling of serum creatinine concentration, every month|End-stage renal disease, anytime when it occurs.|Myocardial infarction, anytime when it occurs.|Coronary revascularization, anytime when it occurs.|Stroke, anytime when it occurs|Hospitalization for unstable angina, anytime when it occurs.|Hospitalization for heart failure, anytime when it occurs.|Death from cardiovascular causes, anytime when it occurs.",,KVT-Study Group,Tokai University|Yokohama City University|Showa University|Kitasato University|St. Marianna University School of Medicine,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,620,
NCT02841280,Chlorthalidone in Chronic Kidney Disease,https://beta.clinicaltrials.gov/study/NCT02841280,CLICK,COMPLETED,YES,"Renal Insufficiency, Chronic|Hypertension",DRUG: Chlorthalidone|DRUG: Placebo,"Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo., Baseline to 12 weeks","Changes in Albuminuria From Baseline at Each 4 Week Visit in the Log Transformed Albumin/Creatinine Ratio in the Chlorthalidone Group Compared to Placebo, Baseline to 12 weeks|Change From Baseline at Each 4 Week Visit in Log of Aldosterone and Log of Renin in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons., Baseline to 12 weeks|Change From Baseline at Each 4 Week Visit in Log of N-terminal Pro B-type Natriuretic Peptide (NTproBNP) in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons., Baseline to 12 weeks|Change From Baseline at Each 4 Week Visit in Body Volume in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons., Baseline to 12 weeks",,Indiana University,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",1507540384,Study Protocol and Statistical Analysis Plan
NCT02448628,A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment,https://beta.clinicaltrials.gov/study/NCT02448628,,COMPLETED,NO,Hypertension,DRUG: CS-3150,"Change from baseline in sitting systolic and diastolic blood pressure, Baseline to end of Week 12","Change from baseline in UACR, Urine Albumin Creatinine Ratio (UACR), Baseline to end of Week 12",,"Daiichi Sankyo, Inc.",,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CS3150-A-J206,
NCT00582777,African American Study of Kidney Disease and Hypertension ABPM Pilot Study,https://beta.clinicaltrials.gov/study/NCT00582777,,COMPLETED,NO,Hypertensive Renal Disease,BEHAVIORAL: USUAL - take your BP Meds as you usually do|BEHAVIORAL: HS DOSING|DRUG: ADD On Dosing,"Night Time Blood Pressure, Night time blood pressure from APBM at weeks 6, 12, and 18","Blood pressure in the clinic Daytime blood pressure, Measured at weeks 6, 12, and 18",,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,"ADULT, OLDER_ADULT",PHASE2|PHASE3,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,AASK ABPM Pilot (completed)|7 U01 KD04868,
NCT01007994,Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients,https://beta.clinicaltrials.gov/study/NCT01007994,,COMPLETED,YES,Hypertension Secondary to Kidney Transplant,"DRUG: New Medication: Enalapril, Isradipine, Propranolol","Number of Participants Who Are Non Dippers, Percentage of subjects in each of the treatment arms who are nondippers, defined as systolic or diastolic nocturnal dip \<10%, 6 months",,,Northwell Health,Children's Hospital of Philadelphia,"CHILD, ADULT",PHASE2|PHASE3,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,09-054,Study Protocol and Statistical Analysis Plan
NCT01918111,"Effects of REnal Denervation for Resistant Hypertension on Exercise Diastolic Function and Regression of Atherosclerosis and the Evaluation of NEW Methods Predicting A successfuL Renal Sympathetic Denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT Trial From RENEWAL RDN Registry)",https://beta.clinicaltrials.gov/study/NCT01918111,,TERMINATED,NO,Resistant Hypertension,PROCEDURE: Renal denervation|DRUG: adenosine infusion treatment,"Change in coronary atheroma, Evaluation of the change in coronary atheroma (change in percent atheroma volume (PAV) and the change in nominal atheroma volume in the 10-mm subsegment with the greatest disease severity at baseline), analyzed by an IVUS, between baseline and 2-year IVUS in the patients with CAD) for RENEWAL-REGRESS trial, change in coronary atheroma for 24 months after renal denervation","Reduction of peak exercise E/E prime, Reduction of peak exercise E/E prime at 6 month follow up for RENEWAL-EXERCISE trial, Peak exercise E/E prime from 6 and 12 months after renal denervation","Evaluation of the novel methods predicting the successful renal sympathetic denervation after RDN, Evaluation of the novel methods predicting the successful or unsuccessful renal sympathetic denervation after RDN: 1) Effects the change of blood pressure by infusion of intra-renal adenosine at pre- and immediate post-RND on blood pressure at 6 and 12 months; 2) Association of skin sympathetic activity measurement before and immediate post-procedure and blood pressure at 6 and 12 months; RENEWAL-PREDICT trial), change of blood pressure at 6 and 12 months",Yonsei University,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,1-2013-0025,
NCT00921570,"The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension",https://beta.clinicaltrials.gov/study/NCT00921570,,COMPLETED,NO,Diabetes|Hypertension|Proteinuria,DRUG: Amlodipine|DRUG: Valsartan,"Flow mediated dilatation, 12 weeks after","TWEAK, PTX-3, Systolic Blood Pressure and Diastolic Blood Pressure, 12 weeks after",,Gulhane School of Medicine,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,GATA VALAMEX study,
NCT01519635,Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension,https://beta.clinicaltrials.gov/study/NCT01519635,,COMPLETED,YES,Hypertension,DRUG: Aliskiren|DRUG: Hydrochlorothiazide,"Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide, Changes in R2\* at between week 0 and week 8 as measured by BOLD MRI in the cortex and medulla of the kidney, week 0 vs week 8",,,Centre Hospitalier Universitaire Vaudois,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011DR3137,
NCT04078711,Chinese Medicine Treat for Hypertensive Renal Injury,https://beta.clinicaltrials.gov/study/NCT04078711,CHAIR,UNKNOWN,NO,Hypertension|Renal Injury,DRUG: Losartan 100Mg Tab|DRUG: Qianyangyuyin 20g Granule|DRUG: placebo,"albumin-to-creatinine ratio(UACR), UACR tested at baseline and each month. Microalbuminuria was defined as urinary ACR of at least 30mg/g., 6 months","Ambulatory blood pressure level, ABPM was measured at baseline, 3 and 6 months. Both systolic and diastolic pressure was assessed. Hypertension was defined as mean ambulatory blood pressure of at least 130/80 mmHg., 6 months|Office blood pressure level 6/5000 Office blood pressure level, Office blood pressure was measured at baseline and each month. Both systolic and diastolic pressure was assessed. Hypertension was defined as office blood pressure of at least 140/90 mmHg., 6 months|Traditional Chinese Medicine syndrome scores, Self reported TCM syndrome scores at baseline and each month. Each main symptom is scored 0ã€2ã€4ã€6 (0 = no sympton; 6 = as heavy as can be), and each secondary symptom is scored 0ã€1ã€2ã€3(0=no symptom; 3= as heavy as can be)., 6 months",,Jiangsu Province Hospital of Traditional Chinese Medicine,Ministry of Science and Technology of the PeopleÂ´s Republic of China|First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,ADULT,PHASE2|PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019NL-086-02,Study Protocol and Statistical Analysis Plan
NCT01184599,A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy,https://beta.clinicaltrials.gov/study/NCT01184599,,UNKNOWN,NO,"Glomerulonephritis, IGA|Hypertension",DRUG: aliskiren,"Renal function (Creatinine clearance), One year (every 6 months)|Urinary protein, One year (every 6 months)","Urinary angiotensinogen, One year (every 6 months)|Urinary type 4 collagen, One year (every 6 months)|Urinary Transforming growth factor-beta, One year (every 6 months)|High-sensitivity C-reactive protein, One year (every 6 months)|Plasma Rennin Activity, One year (every 12 months)|Aldosterone, One year (every 12 months)|Asymmetric dimethylarginine, One year (every 12 months)|Advanced glycation end product, One year (every 12 months)|(Pro)renin receptor, One year (every 12 months)|Oxidative stress, One year (every 12 months)",,Kagawa University,,"CHILD, ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,OCGH-746,
NCT01840540,MSC for Occlusive Disease of the Kidney,https://beta.clinicaltrials.gov/study/NCT01840540,,COMPLETED,NO,Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension,DRUG: Arterial infusion of autologous mesenchymal stem cells,"Renal blood flow and function in the treated kidneys., Individual kidney blood flow, measured by multidetector CT contrast transit times, will be measured before and after MSC infusion., 2 years","Level of kidney function., Level of kidney function will be assessed as glomerular filtration rate by iothalamate clearance. Tissue oxygenation within each kidney will be measured by Blood Oxygen Level Dependent (BOLD) magnetic resonance., 2 years","Blood pressure levels., Blood pressure will be assessed by oscillometric measurement., 2 years",Mayo Clinic,,"ADULT, OLDER_ADULT",PHASE1,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,12-009298,
NCT05687669,Comparison Between the Use of Phentolamine Versus Glyceryl Trinitrate for Their Effect on Renal Function in Pre-eclampsia Patients in ICU,https://beta.clinicaltrials.gov/study/NCT05687669,,NOT_YET_RECRUITING,NO,Pre-Eclampsia; Complicating Pregnancy|Pre-eclampsia Aggravated,DRUG: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment,"kidney function tests, creatinine in micromoles per liter and urea in millimole per liter, 96 hours after intervention",,,Assiut University,,"CHILD, ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,obstetric Renal prophylaxis,
